Before Invest
Merck & Co., Inc. logo

Merck & Co., Inc.

MRK
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance Sheet
Period
Annual Quarterly
Order
Unlock 14 years
Format
% Change
Rows
USD ($)
$ in Millions 		Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Current Assets
                 
Cash and cash equivalents
$ 14,565
$ 13,242
$ 6,841
Short-term investments
0
447
252
Accounts receivable (net of allowance for doubtful accounts of $97 in 2025 and $89 in 2024)
11,775
10,278
10,349
Inventories (excludes inventories of $5,681 in 2025 and $4,193 in 2024 classified in Other assets - see Note 7)
6,658
6,109
6,358
Other current assets
10,518
8,706
8,368
Current assets of discontinued operations
-
-
-
Total current assets
43,516
38,782
32,168
Investments
956
463
252
Property, Plant and Equipment (at cost)
                 
Land
321
307
326
Buildings
17,983
16,360
14,966
Machinery, equipment and office furnishings
19,760
18,283
17,763
Construction in progress
9,166
7,984
8,262
Property, plant and equipment (at cost)
47,230
42,934
41,317
Less: accumulated depreciation
21,914
19,155
18,266
Property, plant and equipment, net
25,316
23,779
23,051
Goodwill
21,579
21,668
21,197
Other Intangibles, Net
26,681
16,370
18,011
Other Assets
18,818
16,044
11,996
Noncurrent Assets of Discontinued Operations
-
-
-
Total Assets
136,866
117,106
106,675
Liabilities and Equity
                 
Current Liabilities
                 
Loans payable and current portion of long-term debt
2,589
2,649
1,372
Trade accounts payable
4,404
4,079
3,922
Accrued and other current liabilities
14,468
15,694
15,766
Income taxes payable
4,726
3,914
2,649
Dividends payable
2,140
2,084
1,985
Current liabilities of discontinued operations
-
-
-
6% Mandatory convertible preferred stock, $1 par value Authorized - 11,500,000 shares issued and outstanding - 855,422 shares
-
-
-
Total current liabilities
28,327
28,420
25,694
Long-Term Debt
46,750
34,462
33,683
Deferred Income Taxes
1,439
1,387
871
Other Noncurrent Liabilities
7,688
6,465
8,792
Noncurrent Liabilities of Discontinued Operations
-
-
-
Deferred Income Taxes and Noncurrent Liabilities
-
-
-
Merck & Co., Inc. Stockholders’ Equity
                 
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2025 and 2024
1,788
1,788
1,788
Other paid-in capital
45,029
44,704
44,509
Retained earnings
73,075
63,069
53,895
Accumulated other comprehensive loss
(4,287)
(4,945)
(5,161)
Stockholders' equity before deduction for treasury stock
115,605
104,616
95,031
Less treasury stock, at cost: 1,102,476,756 shares in 2025 and 1,049,466,187 shares in 2024
62,999
58,303
57,450
Total Merck & Co., Inc. stockholders’ equity
52,606
46,313
37,581
Noncontrolling Interests
56
59
54
Total equity
52,662
46,372
37,635
Total Liabilities and Equity
$ 136,866
$ 117,106
$ 106,675